tivozanib
jazz,aveo oncology,kyowa kirin
['fotivda', 'tivozanib']
 presented three posters at the 2022 annual meeting, highlighting data for fotivda (tivozanib), the company s first -approved therapy. additional phase 2 and phase 3 data was reported. #pharma #biotech #clinicaltrials #oncology
AVEO Oncology is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology & other areas of unmet medical need